Our portfolio

Amplio Pharma

Amplio Pharma’s proprietary NovoBio Med technology amplifies the efficacy of methotrexate (MTX), the first line, cornerstone drug used to treat a wide variety of autoimmune diseases. NovoBioMed is able to trap MTX at its target, resulting in a faster response and better efficacy at a lower dose.

Industry: Rheumatology, Therapeutics

Want to get in contact about Amplio Pharma?

We’re happy to connect. Reach out to our investment manager working with the team to learn more or explore potential opportunities.

Marc Roelofs

Life Science & Health

Our portfolio

Check out similar ventures

Providing quantum-safe security solutions to protect organizations from future cyber threats.
Developing bispecific antibodies as enhanced cancer immunotherapy.
Pioneering gene therapy, uniQure develops transformative treatments using its AAV-based technology platform.
Upcycling phosphate waste into sustainable industrial products.
Providing quantum-safe security solutions to protect organizations from future cyber threats.
Developing bispecific antibodies as enhanced cancer immunotherapy.
Pioneering gene therapy, uniQure develops transformative treatments using its AAV-based technology platform.
Upcycling phosphate waste into sustainable industrial products.